Recently, a Phase 1 clinical trial of MOv18 IgE demonstrated a very good safety profile in patients with tumors expressing FRα and provided early evidence of clinical response.48 A Phase 1b study in platinum-resistant ovarian cancer is currently recruiting (Table 1). This evidence concerns the gene FOLR1 and ovarian carcinoma.